Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. - Wikidata - wikimedia - TriplyDB

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.

http://www.wikidata.org/entity/Q35994416

about

Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.The aqueous extract of Brucea javanica suppresses cell growth and alleviates tumorigenesis of human lung cancer cells by targeting mutated epidermal growth factor receptor.Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer.Stereotactic body radiotherapy for oligoprogressive cancer.Targeting the EGFR T790M mutation in non-small-cell lung cancer.A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition.Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter Legomedicine-A Versatile Chemo-Enzymatic Approach for the Preparation of Targeted Dual-Labeled Llama Antibody-Nanoparticle Conjugates Understanding the Precision in "Precision Medicine"Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC.Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.FLNa negatively regulated proliferation and metastasis in lung adenocarcinoma A549 cells via suppression of EGFR.Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.The regulatory role of APE1 in epithelial-to-mesenchymal transition and in determining EGFR-TKI responsiveness in non-small-cell lung cancer

P2860

Q26741846-C5094C6E-CC4A-4ABA-A956-A0517AD58672 Q33618558-FE873D24-7B06-4200-AD38-9FA0799321B1 Q33880574-0F2173E2-5EE0-4C5A-B7AD-366BF7D43952 Q37397842-4117FD0F-6B91-4386-9984-10E32B22E971 Q37565357-7F34DC25-CF64-4DF0-87BD-5A0DBE4D0921 Q37580344-47EC7D4B-B721-474A-BE66-4B7C83F67C0E Q37581008-C07D8512-F906-4B5E-90AA-0BDA80897372 Q38682189-13EB9D24-3FD0-4BEE-8CD7-1F68B93F013B Q38707122-86D4E81F-E7CF-41DD-B21D-CC456072DD45 Q38709287-A2515148-561E-4DA1-9AA1-71C65B636D76 Q38745430-1C33519D-93A9-4312-91A6-9D5D770678AE Q38746756-17502C53-B324-4756-9CF2-698522677F23 Q38756349-40C3AD85-AD35-4F4B-8606-485CDC52758C Q38935913-13396463-00E6-4F04-B3B9-F097C89A05FB Q39047294-BEEB06AB-0D69-41EC-8AF2-E09CE4DD423D Q41563298-FCF39EC5-C4EB-488A-8729-FB53707ABCE3 Q42316038-EE7304F8-6CD3-4E4B-ACDC-1332DB37B1D1 Q42319260-8E5D1A79-57E1-4485-BA35-3462833DF497 Q42396908-A3445C84-AD77-46EE-AAE1-189E67EFBA7A Q47119773-E48C00D5-6DED-4ECF-B46A-D57A67F643BE Q47134648-B6100F2A-3639-46BB-B559-4E22A7A72BAA Q47260594-1B25444E-366E-4D4A-844A-06871564F765 Q47671139-8B7D4610-C3E3-4F74-9D1C-FA8259E98D68 Q48021721-2BD1B5F6-B2F7-4E56-B317-8B1B6811CC29 Q58779784-51D9D16E-6E3A-48A6-A048-D3B27F8D913E

P2860

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.

http://www.wikidata.org/entity/Q35994416

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.

@ast

Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.

@en

type

label

Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.

@ast

Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.

@en

prefLabel

Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.

@ast

Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.

@en

P1433

Q35994416-0FC0310B-8222-4D31-A34F-F912880E030C

P1476

Q35994416-73917D28-27ED-40D4-928F-AC135B4D46EC

P2093

Q35994416-02D356AE-D869-4C3F-9C30-5AB2A87F42A3

Q35994416-08ABE7E8-7020-415B-A3C4-24DCECAC4B78

Q35994416-0B58CD72-A93A-42C2-A529-50E81ED1EA5D

Q35994416-2A89619E-EBAB-4A50-AFE1-FB78CD42F029

Q35994416-379BF9F2-9FFA-474F-8A4D-154377711A0A

Q35994416-4F79B01E-15C8-4FEE-B345-D3D29158E163

Q35994416-579EC637-521D-42E5-8391-C7C2588EEBD5

Q35994416-63C338C8-6DAA-4B1A-AEC3-E8EC7D254534

Q35994416-6BD53D49-DB08-4252-AE8D-A11BDFE03DC4

Q35994416-7C600C1A-B75A-4F79-82A8-7DDD5AF1511C

P2860

Q35994416-054BA320-CC99-4A45-9B20-8B58D028B1AF

Q35994416-0B01ED8D-1CBD-46BA-B297-64EE5950CF62

Q35994416-11641090-E2D9-4B29-A2AD-6255FBCB748C

Q35994416-12305D9A-2646-43AB-96B6-AF2754464D4A

Q35994416-19455B0C-175D-472D-BC6C-67AB6DFBCF15

Q35994416-1BBA282A-B146-4189-B65D-6831C5379AD3

Q35994416-1BF950B0-93B6-4A1E-BD94-052CA0586FAF

Q35994416-1D031CE4-4608-406E-AE5C-846CC3D4EA4B

Q35994416-1D44AFF5-5EEC-4052-AEAF-D8FDA9C451B0

Q35994416-2663AC56-AFBC-4F33-A305-758A30D964BF

P304

Q35994416-8856FE95-14AC-431B-AB0B-3DB909897B2C

P31

Q35994416-9CC17F0E-1C38-4362-BC31-E8CEF93E66D5

P356

Q35994416-37561FFD-70E5-4B35-802C-0FF8970A475E

P407

Q35994416-89F9AC3F-6CEF-471D-96A0-2BBC800D3C8C

P433

Q35994416-E4F07DFA-5194-46E7-9156-F4F97F53BA2A

P478

Q35994416-CA29C716-0370-4340-9BA1-7755488D6C88

P50

Q35994416-39103430-1EDD-4D04-8BB0-7C5463C6BCC0

Q35994416-93D3E10D-4E1E-4643-B447-2EAD2DBBA845

P577

Q35994416-7DBE687B-1BBD-4997-8F82-530184999804

P698

Q35994416-508F1CFC-9996-444E-AFDA-AD9780B4BBEC

P932

Q35994416-285D6B14-9F05-424E-9460-5150FCCD0E85

P356

0008-5472.CAN-15-0377

P1433

Cancer Research

P1476

Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.

@en

P2093

Chunxiao Xu

http://www.w3.org/2001/XMLSchema#string

Cloud P Paweletz

http://www.w3.org/2001/XMLSchema#string

Eiki Kikuchi

http://www.w3.org/2001/XMLSchema#string

Fatima Al-Shahrour

http://www.w3.org/2001/XMLSchema#string

Geoffrey I Shapiro

http://www.w3.org/2001/XMLSchema#string

Inés Pulido

http://www.w3.org/2001/XMLSchema#string

Jeffrey H Becker

http://www.w3.org/2001/XMLSchema#string

Julián Carretero

http://www.w3.org/2001/XMLSchema#string

Margaret Soucheray

http://www.w3.org/2001/XMLSchema#string

Marzia Capelletti

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

The basics of epithelial-mesenchymal transition

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

P304

4372-4383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-15-0377

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26282169

http://www.w3.org/2001/XMLSchema#string

P932

4548796

http://www.w3.org/2001/XMLSchema#string